‏إظهار الرسائل ذات التسميات Dermatology. إظهار كافة الرسائل
‏إظهار الرسائل ذات التسميات Dermatology. إظهار كافة الرسائل

How to Compare Hair Loss Treatment Options Before You Start

How to Compare Hair Loss Treatment Options Before You Start

Hair loss is one of those problems that sneaks up on you. You notice a little more on the pillow, slightly more in the drain, and then one day you're standing in front of the mirror wondering how long this has actually been happening. The instinct is to do something, anything, fast. But how you choose a treatment matters as much as choosing one at all. Picking the wrong approach can waste months, and in some cases, make things worse.

Not All Hair Loss Is the Same

Before comparing any treatment, it helps to understand that hair loss is not a single condition. It has different types, different causes, and different mechanisms.
  • Androgenetic alopecia: driven by genetics and hormones, specifically the way DHT affects hair follicles over time.
  • Telogen effluvium: stress or deficiency-related shed where too many follicles enter the resting phase at once.
  • Alopecia areata: autoimmune.
  • Traction alopecia: physical.
Why does this matter? Because a treatment designed for hormonal hair loss will do nothing for a nutritional deficiency. And a treatment targeting deficiency will not address an autoimmune trigger.

What the Common Treatments Actually Do

Most people encounter the same short list of treatments early in their research. Here is an honest look at what each one actually targets:
  • Minoxidil: increases blood flow to the scalp, prolonging the growth phase of hair follicles. Requires continued use to maintain results.
  • Finasteride: blocks conversion of testosterone to DHT. Effective for androgenetic alopecia in men but may cause hormonal side effects.
  • Nutritional supplements: work only when deficiency (iron, vitamin D, biotin) is present. Extra intake does not accelerate growth if levels are normal.
  • PRP therapy: uses platelet-rich plasma to stimulate follicle activity. Promising but expensive, requires multiple sessions, and results vary.
  • Hair transplants: surgical and permanent, redistributing existing hair. Not effective if the underlying cause is still active.

Why People Choose the Wrong Treatment

The most common mistake is choosing based on marketing rather than mechanism. A product that promises regrowth in 30 days is not explaining why your hair is falling, it is just offering a result.

Another mistake is treating hair loss as only a scalp issue. The scalp is where the symptom appears, but the cause is often systemic. Hormonal imbalance, chronic stress, gut health, thyroid function, and diet all influence the hair cycle in real ways.

How to Actually Compare Your Options

When looking at hair fall treatment options, the comparison should be structured around a few honest questions:
  • Does this treatment match the type of hair loss I have?
  • Does it address the cause or just the symptom?
  • What is the expected timeline, and is that realistic?
  • Are there side effects I need to weigh carefully?
  • Is this sustainable long-term, or am I dependent on it indefinitely?

Where Root-Cause Thinking Changes the Approach

Some platforms are built specifically around treating hair loss from the inside out. Traya combines Ayurvedic, medical, and nutritional approaches together, which reflects an understanding that hair loss is rarely caused by just one thing. That kind of layered thinking tends to produce more durable results than any single product used in isolation.

Final Thoughts

Comparing hair loss treatments is not just about picking the most popular option or the one with the best reviews. It is about understanding what is actually driving your hair loss and then finding an approach that genuinely addresses it. The best treatment for someone else may be irrelevant for you. Start with understanding, and the right decision becomes much clearer.

Dermocosmetics Startup Led by Renowned Dermatologist Dr. Chytra Anand Secures Seed Round Investment Led by Inflection Point Ventures

Dermocosmetics Startup Led by Renowned Dermatologist Dr. Chytra Anand Secures  Seed Round Investment Led by Inflection Point Ventures
(L-R)  Meera Iyer, Co-Founder & CEO, Dr. Chytra Anand, Founder & Chief Formulator
  • SkinQ offers dermatologically tested solutions tailored specifically for melanin-rich skin to enhance confidence and well-being for millions worldwide.
  • The funds will be utilised towards new product launches, research and development, team expansion, and brand enhancement.
  • SkinQ secured a finalist spot at the esteemed Beauty & You awards by Estee Lauder & Nykaa in November '23.
  • Inflection Point Ventures (IPV) has so far invested over INR 650 Cr across 200+ deals.
In a significant boost to the burgeoning personalized skincare market, SkinQ Dermo cosmetics has secured a seed investment led by Inflection Point Ventures with participation from Venture catalysts and Super Angels. This funding round marks a milestone in SkinQ's journey to bring cutting-edge dermo cosmetics solutions to the market.

Founded by the globally acclaimed dermatologist Dr. Chytra V Anand, SkinQ is not just a pioneering brand but a movement towards redefining skincare standards. The company's ethos is rooted in empowering individuals with melanin-rich skin, enhancing their confidence and well-being. With its mission to elevate the Skin Quotient of 10 million customers in the next three years, SkinQ is setting a new precedent in the industry with Clinically tested and proven solutions for Skin of Colour. SkinQ is bringing dermatologist expertise to the homes of the consumers with solutions for common skin concerns. 

The seed capital from IPV is pivotal for SkinQ's aggressive expansion plans. The funds will be strategically channelled towards launching innovative products, ramping up research and development, expanding the team, and enhancing the brand’s market presence. This investment signifies a transformative phase for SkinQ, poised to disrupt the traditional skincare market with its unique focus on melanin-rich skin.

SkinQ is spearheaded by 2 Women of renown in their fields. Founder & Chief formulator, Dr. Chytra Anand, a globally renowned Dermatologist and a leading skin influencer is the visionary force behind SkinQ, leveraging her expertise as a skin of colour expert and acclaimed award winning dermatologist.

Co-Founder & CEO, Meera Iyer, equipped with a B.Sc in Chemistry and Biotechnology, and an MMS in Marketing, complements the venture with her strategic acumen, serving as an instrumental co-founder shaping SkinQ's growth trajectory leveraging her expertise from Unilever, Big basket and Medlife CMO & CBO roles.

Ivy Chin, Partner, Inflection Point Ventures, says, “By embracing the melanin-rich skin of Indians, SkinQ aims to revolutionise skincare by recognizing the unique needs of Indians . By addressing the distinct requirements of the melanin-rich skin, SkinQ has the potential to captivate the hearts of millions, who can truly appreciate the difference in its products.”

SkinQ achieved a significant operational milestone, growing MOM in their revenues, marking substantial growth and success in its endeavours with a discerning customer base and new channels of distribution. SkinQ is the first Indian Origin Dermo Cosmetics brand retailing in Dermatology offices & MedSpas in USA.

It boasts a unique array of strengths and USPs, including clinically proven functional Dermo Cosmetic solutions known for their efficacy. As the brainchild of a dermatologist, the brand stands out as the first to specifically formulate and test products addressing concerns of skin of colour, setting a pioneering standard in the industry.

Dr. Chytra Anand, Founder, SkinQ, says, “Everyone deserves to have healthy glowing skin and access to best in the class solutions celebrating the diversity and uniqueness of Indian skin and melanin rich skin. With over 2/3 of the world’s population being Melanin rich there is an under representation with only 8% of skin solutions solving for them globally.

“The alliance with IPV & our investors is a strategic enabler in our quest to redefine the skincare paradigm through a fusion of scientific ingenuity and technological innovation. This capital infusion is pivotal in augmenting our research and development bandwidth, enriching our bespoke product portfolio, and amplifying our outreach to a discerning customer base.”

We are building a multi-dimensional approach to be present at various touch points of our customers skin health journey in the fasting growing segment today.”

SkinQ garnered notable recognition in the beauty industry, securing finalist positions at esteemed events like Estee Lauder & Nykaa's Beauty & You awards and the D2C Innovation Awards underscoring its innovative approach. Additionally, its sunscreens have received accolades, ranking as the top choices—voted as the top 5 by Vogue Beauty Awards and top 4 by Elle Beauty awards—solidifying SkinQ's commitment to quality and effectiveness in skincare.

The Dermo Cosmetics market in India showed substantial growth, rising from $188 million in 2021 to an anticipated $450 million by 2030, indicating a significant upward trajectory. Globally, the industry was valued at $51 billion in 2021, forecasted to reach an impressive $130 billion by 2030, showcasing substantial expansion and potential for the coming years.

About SkinQ: Founded by Dr. Chytra V Anand, an internationally recognized dermatologist, SkinQ focuses on delivering skincare solutions based on individual skin needs for Skin of Colour concerns.

Combining scientific research with innovative technology, SkinQ aims to set new standards in the skincare industry with proprietary novel formulations.

About Inflection Point Ventures & Physis Capital

Inflection Point Ventures (IPV) is an angel investing platform with over 9600 CXOs, HNIs, and Professionals who together invest in startups. The firm supports new-age entrepreneurs by providing them with monetary & experiential capital and connecting them with a diverse group of investors. IPV has announced the launch of a $50 million CAT 2 AIF, Physis Capital, to invest in pre-Series A to Series B growth-stage start-ups.

Market Reports

Market Report & Surveys
IndianWeb2.com © all rights reserved